Pharvaris N.V. (PHVS) stock
PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$32.28−0.16 (-0.49%)
Close on Nov 17, 2026Market cap $2.11BP/E –Yield –
Pharvaris operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€173.71M. The highest annual figure on record is -€4.31M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€173.71M | – |
| FY2024 | Dec 31, 2024 | -€132.40M | – |
| FY2023 | Dec 31, 2023 | -€99.83M | – |
| FY2022 | Dec 31, 2022 | -€75.65M | – |
| FY2021 | Dec 31, 2021 | -€42.66M | – |
| FY2020 | Dec 31, 2020 | -€26.07M | – |
| FY2019 | Dec 31, 2019 | -€8.03M | – |
| FY2018 | Dec 31, 2018 | -€4.31M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€47.24M | – |
| Q2 FY2025 | Jun 30, 2025 | -€45.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -€29.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -€21.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -€9.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -€15.20M | – |
See a number that looks wrong?